您的购物车内没有物品。
DNA-PK
Catalog No. | Product Name | Application | Product Information |
---|---|---|---|
A10726 SALE |
PI-103 |
PI3K 抑制剂 |
PI-103 is a potent, cell-permeable, ATP-competitive inhibitor of phosphatidylinositol 3-kinase (PI3K) family members with selectivity toward DNA-PK, PI3K (p110α), and mTOR.
|
A12752 SALE |
NU7026 |
DNA-PK 抑制剂 |
NU7026 is a novel DNA-dependent protein kinase inhibitor that potentiates the cytotoxicity of topoisomerase II poisons used in the treatment of leukemia.
|
A13328 |
ETP-46464 |
ATR 抑制剂 |
ETP-46464 is a potent and selective inhibitor of ATR with IC50 of 25 nM.
|
A13224 SALE |
KU 0060648 |
DNA-PK 抑制剂 |
KU0060648 is a potent and selective inhibitor of DNA-dependent protein kinase (DNA-PK), (IC50 = 8.6 nM); with 20-1000 fold selectivity for DNA-PK over other PIKKs and a panel of 60 kinases. KU-0060648 enhances HDR efficiency and attenuates NHEJ frequency.
|
A11778 |
Compound 401 |
DNA-PK 抑制剂 |
Compound 401 is a cell-permeable pyrimido-isoquinolinone compound that acts as a potent, reversible, and ATP-competitive inhibitor of DNA-PK (IC50 = 280 nM) with ~19-fold selectivity over mTOR (IC50 = 5.3 ?M).
|
A10729 |
PIK-75 |
PI3K 抑制剂 |
PIK-75 is an imidazopyridine that selectively inhibits p110α with an IC50 value of 5.8 nM.2 It inhibits p110γ and p110β considerably less effectively with IC50 values of 0.076 µM and 1.3 µM, respectively.
|
A11207 SALE |
PP121 |
PI3K 抑制剂 |
PP121 is a dual inhibitor of receptor tyrosine kinases (RTKs) (IC50 < 0.02 μM for Abl, Src, VEGFR-2 and PDGFR) and PI 3-K family kinases (IC50 < 0.06 μM for p110α, DNA-PK and mTOR).
|
A11098 SALE |
NU-7441 (KU-57788) |
DNA-PK 抑制剂 |
NU-7441 (KU-57788) is a potent and selective DNA-dependent protein kinase (DNA-PK) inhibitor. The IC50 values are 14, 1700, 5000, >100000 and >100000 nM for DNA-PK, mTOR, PI 3-K, ATM and ATR respectively.
|
A15779 |
CC-115
|
mTOR/DNA-PK 抑制剂 |
CC-115 is a inhibitor of mTOR/DNA-PK (IC50= 21/ 13 nM).
|
A14136 |
NU6027 |
ATR/CDK inhibito |
NU6027 is a potent inhibitor of cellular ATR activity (IC(50)=6.7 μM) and enhanced hydroxyurea and cisplatin cytotoxicity in an ATR-dependent manner.
|